Investigational drug · Phase 2
Botensilimab
Also called: AGEN1181, 8541A
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
39
Any phase or sponsor naming "Botensilimab"
First trial start
2022
Nov 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Botensilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer
- Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
- Untreated
- Advanced Pancreatic Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Botensilimab" as an intervention, largest first.
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruiting
Agenus Inc.Industry
NCT03860272 · 499 participants · Start Mar 20, 2019 · Primary completion Jan 13, 2025
Drug: Botensilimab; Balstilimab · For: Advanced Cancer; Angiosarcoma; Colorectal Cancer Without Liver Metastases and 5 more
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 18 sites in all
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07227636 · 284 participants (planned) · Start Nov 7, 2025 · Primary completion Nov 2030
Drug: Botensilimab; Balstilimab · For: Colorectal Cancer; Rectal Cancer
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerPivotal-lookingActive, not recruiting
Agenus Inc.Industry
NCT05608044 · 234 participants · Start Nov 30, 2022 · Primary completion Sep 2027
Drug: Botensilimab; Balstilimab and 1 more · For: Metastatic Colorectal Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 65 sites in all
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Recruiting
Gruppo Oncologico del Nord-OvestAcademic, hospital or other
NCT05845450 · 197 participants (planned) · Start May 11, 2023 · Primary completion May 2027
Drug: Trastuzumab deruxtecan; Durvalumab and 9 more · For: Colorectal Cancer; Resectable Colorectal Carcinoma
Sites: Milan, Italy
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaPivotal-lookingTerminated
Agenus Inc.Industry
NCT05529316 · 150 participants · Start Dec 12, 2022 · Primary completion Apr 27, 2026
Drug: Botensilimab; Balstilimab · For: Advanced Melanoma
Sites: Scottsdale, Arizona; Fullerton, California; Santa Monica, California · 51 sites in all
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsPivotal-lookingRecruiting
The Netherlands Cancer InstituteAcademic, hospital or other
NCT06279130 · 133 participants (planned) · Start Jan 29, 2024 · Primary completion Jan 29, 2029
Drug: botensilimab; balstilimab and 1 more · For: Resectable MMR-deficient Solid Tumors; Resectable MMR-proficient Solid Tumors
Sites: Amsterdam, Netherlands
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasPivotal-lookingRecruiting
Centre Leon BerardAcademic, hospital or other
NCT06346197 · 132 participants (planned) · Start Dec 8, 2025 · Primary completion May 15, 2028
Drug: Balstilimab; Botensilimab and 3 more · For: Gastric Cancer; MSI-H; Metastatic Cancer and 1 more
Sites: Brest, France; Clermont-Ferrand, France; Lyon, France · 7 sites in all
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialPivotal-lookingSuspended
Michael B. Atkins, MDAcademic, hospital or other
NCT05928806 · 120 participants (planned) · Start Sep 25, 2023 · Primary completion Nov 10, 2026
Drug: Botensilimab; Balstilimab and 2 more · For: Advanced Renal Cell Carcinoma
Sites: La Jolla, California; New Haven, Connecticut; Washington D.C., District of Columbia · 13 sites in all
City of Hope Medical CenterAcademic, hospital or other
NCT07595874 · 100 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 16, 2028
Drug: Balstilimab; Botensilimab · For: Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma and 10 more
Sites: Goodyear, Arizona; Corona, California; Duarte, California · 11 sites in all
Agenus Inc.Industry
NCT04121676 · 91 participants · Start Sep 26, 2019 · Primary completion Feb 22, 2024
Drug: AGEN2373; Botensilimab · For: Advanced Cancer
Sites: Los Angeles, California; Aurora, Colorado; Coral Gables, Florida · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair-Proficient and -Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial.
Shah MA, Hissong E, Jafari MD, et al. · Clin Cancer Res 2026
- Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases.
Schlechter BL, Fakih MG, Tsimberidou AM, et al. · Clin Cancer Res 2026
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial.
Ghelardi F, Ambrosini M, Raimondi A, et al. · Nat Med 2026
- Immunotherapy in Colorectal Cancer: Novel Perspectives and Next Steps.
de Almeida TSC, Braghiroli MIMF, Sabbaga J, et al. · Am J Clin Oncol 2026
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.
Konecny T, Zadirako N, Grigoryan A, et al. · Oncogene 2026
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.
El-Deiry WS, Hernando-Calvo A, Dizon D, et al. · Oncotarget 2026
Also in development for Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.